Francis Cano Biography and Net Worth

Director of Dynavax Technologies

Dr. Cano was appointed to the Dynavax board in November 2009. Dr. Cano is President and Founder of Cano Biotech Corp., a consulting firm focusing on the vaccine business, and also serves on the boards of Biomerica, Inc., a developer and manufacturer of diagnostic products, and Arbor Vita Corporation, a biopharmaceutical company. From 1993 to 1996, Dr. Cano was President and Chief Operating Officer for Aviron, a biopharmaceutical company, which was later acquired by MedImmune in 2001. As a Co-Founder of Aviron, he completed two rounds of venture financing, a licensing agreement with SmithKline Biologicals and in-licensed Flu-Mist influenza vaccine from the National Institutes of Health. For 21 years, Dr. Cano worked with the Lederle Laboratories Division of American Cyanamid, most recently as Vice President and General Manager of the Biologicals unit. He earned a Ph.D. in Microbiology from Pennsylvania State University, served as a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in Microbiology and a B.S. in Biology from St. John's University.

What is Francis Cano's net worth?: The estimated net worth of Francis Cano is at least $402,264.50 as of May 31st, 2024. Dr. Cano owns 36,905 shares of Dynavax Technologies stock worth more than $402,265 as of April 24th. This net worth approximation does not reflect any other assets that Dr. Cano may own. Learn More about Francis Cano's net worth.
How do I contact Francis Cano?: The corporate mailing address for Dr. Cano and other Dynavax Technologies executives is 2100 Powell Street Suite 900, Emeryville CA, 94608. Dynavax Technologies can also be reached via phone at (510) 848-5100 and via email at ir@dynavax.com. Learn More on Francis Cano's contact information.
Has Francis Cano been buying or selling shares of Dynavax Technologies?: Francis Cano has not been actively trading shares of Dynavax Technologies over the course of the past ninety days. Most recently, Francis Cano sold 3,615 shares of the business's stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.93, for a transaction totalling $43,126.95. Following the completion of the sale, the director now directly owns 36,905 shares of the company's stock, valued at $440,276.65. Learn More on Francis Cano's trading history.
Who are Dynavax Technologies' active insiders?: Dynavax Technologies' insider roster includes Justin Burgess (Insider), Francis Cano (Director), Andrew Hack (Director), Robert Janssen (SVP), Kelly MacDonald (Sr. VP & CFO ), David Novack (COO), and Ryan Spencer (CEO). Learn More on Dynavax Technologies' active insiders.
Are insiders buying or selling shares of Dynavax Technologies?: In the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 3,615 shares worth more than $43,126.95. The most recent insider tranaction occured on May, 31st when Director Francis Cano sold 3,615 shares worth more than $43,126.95. Insiders at Dynavax Technologies own 3.0% of the company. Learn More about insider trades at Dynavax Technologies.
Information on this page was last updated on 5/31/2024.

Francis Cano Insider Trading History at Dynavax Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2024	Sell	3,615	$11.93	$43,126.95	36,905
8/8/2022	Sell	15,000	$17.17	$257,550.00	20,834
8/12/2019	Buy	16,667	$3.00	$50,001.00	118,484
12/6/2018	Sell	2,000	$10.47	$20,940.00

Francis Cano Buying and Selling Activity at Dynavax Technologies

Dynavax Technologies Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Today's Range

Now: $10.90

$10.68

$11.10

50 Day Range

MA: $12.86

$10.30

$14.40

2 Week Range

Now: $10.90

$9.74

$14.63

Volume

2,410,776 shs

Average Volume

2,195,177 shs

Market Capitalization

$1.35 billion

P/E Ratio

60.56

Dividend Yield

N/A

Beta

1.26